OREX Orexigen Therapeutics, Inc.

3.10
+0  (4%)
Previous Close 2.98
Open 3.05
Price To book 0.76
Market Cap 47.20M
Shares 15,227,000
Volume 209,880
Short Ratio 10.41
Av. Daily Volume 413,432

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17763020
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17725775
  3. 8-K - Current report 17725701
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17723324
  5. 8-K - Current report 17719360

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 11 2014. CV outcomes trial terminated May 2015. New safety trial CONVENE initiated 2016. Due to be completed January 2022.
Contrave
Obesity

Latest News

  1. Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017
  2. Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada
  3. ETFs with exposure to Orexigen Therapeutics, Inc. : April 17, 2017
  4. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  5. Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
  6. Orexigen Releases Q4 Results, Vivus Reacquires Stendra from Sanofi
  7. Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y
  8. Edited Transcript of OREX earnings conference call or presentation 28-Mar-17 9:00pm GMT
  9. Orexigen reports 4Q loss
  10. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  11. Orexigen Inks Commercialization Deal for Contrave, Stock Up
  12. Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy
  13. How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma
  14. Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017
  15. Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and Orexigen Therapeutics
  16. Orexigen Therapeutics to Speak at Upcoming Investor Conferences
  17. Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A.
  18. Orexigen Therapeutics (OREX) Shares March Higher, Can It Continue?

SEC Filings

  1. CT ORDER - Confidential treatment order 17763020
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17725775
  3. 8-K - Current report 17725701
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17723324
  5. 8-K - Current report 17719360
  6. 8-K - Current report 17673851
  7. D - Notice of Exempt Offering of Securities 17660857
  8. 8-K - Current report 17637159
  9. 8-K - Current report 17619844
  10. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17601941